



Cancer Research Center of Hawai'i
UNIVERSITY OF HAWAI'I

Prevention and Control Program

December 15, 2004

David Backstrom, ND
President/CEO
Resort Health Products Ltd.
211 Napoko Place
Kula, Maui, Hawaii 96790

Dear David,

Thank you for supplying Noni Maui capsules for our continuing Phase I dose finding clinical trial in patients with advanced cancer.

As I mentioned, the benefit to Resort Health Products Ltd., Noni Maui is that I will acknowledge the use of your product in the publication of our results as well as to patients and the public enquiring about the study.

This will clearly distinguish your product as being:

1) Of a high enough quality to be used in bone fide scientific research in humans. Over the last three years I have had many enquiries about the product we were using for our first Phase I study, Innovative Nutraceuticals Kahu Noni. However, I was told that it wasn't commercially available under that name when people looked for it.

2) If results show a benefit for cancer patients then your product would gain the most since it is well recognized that there are differences between the multiple marketed products now available. This is of course is a potential benefit depending on study results.

After speaking with Dr. Hornick and reading his publication on the anti-angiogenesis effects of a concentrated "Super Noni" product, I am excited by his findings. As the results of your testing unfold, I would be happy to work with you to develop a clinical testing strategy for Super Noni that would build on the findings of our current study.

Kind regards,

Brian F. Issell, MD, FACP
Professor of Medicine & Director, Clinical Trials Unit